Literature DB >> 34788749

Dynamics of Circulating miR-122 Predict Liver Cancer and Mortality in Japanese Patients with Histopathologically Confirmed NAFLD and Severe Fibrosis Stage.

Norio Akuta1, Yusuke Kawamura1, Fumitaka Suzuki1, Satoshi Saitoh1, Yasuji Arase1, Nozomu Muraishi1, Shunichiro Fujiyama1, Hitomi Sezaki1, Tetsuya Hosaka1, Masahiro Kobayashi1, Mariko Kobayashi2, Yoshiyuki Suzuki1, Kenji Ikeda1, Hiromitsu Kumada1.   

Abstract

INTRODUCTION: It is unclear whether the relationships between changes in fibrosis and circulating microRNA-122 (miR-122) dynamics might influence the prognosis of nonalcoholic fatty liver disease (NAFLD).
METHODS: This study investigates the impact of serum miR-122 dynamics and histological changes on the incidence of liver cancer and mortality in 81 Japanese NAFLD patients who underwent serial liver biopsies. The median interval between the first and second liver biopsies was 2.9 years.
RESULTS: The fibrosis stage scores indicated progression, no change, and improvement (a decrease of one point or more) in 21.0%, 56.8%, and 22.2% of the patients, respectively. There were 64 patients in the high-risk group who had no improvement in stage scores. Among these, the miR-122 levels were significantly lower in 7 patients with liver cancer than those of the 54 patients who had no liver cancer at the second liver biopsy. The cumulative rates of liver cancer were significantly higher in cases with miR-122 ratios <0.5 (serum miR-122 level at second biopsy to that at first biopsy) than those with ratios ≥0.5. The cumulative survival rates in cases with miR-122 ratios <0.5 tended to be lower than those with ratios ≥0.5. Of the 64 high-risk patients, 39 indicated stage 2 or greater (severe fibrosis stage) at the first liver biopsy and also showed similar results of cumulative liver cancer and survival rates.
CONCLUSIONS: Longitudinal examination of serial liver biopsies indicated that the circulating miR-122 dynamics might be useful in predicting the prognosis for NAFLD patients with severe fibrosis stage and no improvement of the stage scores.
© 2021 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Dynamics; Liver cancer; Mortality; Nonalcoholic fatty liver disease; Serial liver biopsy; microRNA-122

Mesh:

Substances:

Year:  2021        PMID: 34788749      PMCID: PMC8820428          DOI: 10.1159/000519995

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  27 in total

Review 1.  Nonalcoholic fatty liver disease.

Authors:  Paul Angulo
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

Review 2.  miR-122--a key factor and therapeutic target in liver disease.

Authors:  Simonetta Bandiera; Sébastien Pfeffer; Thomas F Baumert; Mirjam B Zeisel
Journal:  J Hepatol       Date:  2014-10-13       Impact factor: 25.083

3.  MicroRNAs as possible biomarkers for hepatocellular carcinoma.

Authors:  Asahiro Morishita; Tsutomu Masaki
Journal:  Hepatol Res       Date:  2018-06       Impact factor: 4.288

4.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

5.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

6.  Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma.

Authors:  Verena Köberle; Bernd Kronenberger; Thomas Pleli; Jörg Trojan; Esther Imelmann; Jan Peveling-Oberhag; Martin-Walter Welker; Mohammed Elhendawy; Stefan Zeuzem; Albrecht Piiper; Oliver Waidmann
Journal:  Eur J Cancer       Date:  2013-06-26       Impact factor: 9.162

7.  Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis.

Authors:  Carlos J Pirola; Tomas Fernández Gianotti; Gustavo O Castaño; Pablo Mallardi; Julio San Martino; María Mora Gonzalez Lopez Ledesma; Diego Flichman; Faridodin Mirshahi; Arun J Sanyal; Silvia Sookoian
Journal:  Gut       Date:  2014-06-27       Impact factor: 23.059

8.  Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease.

Authors:  Silvia Cermelli; Anna Ruggieri; Jorge A Marrero; George N Ioannou; Laura Beretta
Journal:  PLoS One       Date:  2011-08-23       Impact factor: 3.240

9.  The clinical significance of microRNA-122 in predicting the prognosis of patients with hepatocellular carcinoma: A meta-analysis validated by the Cancer Genome Atlas dataset.

Authors:  Yanfang Zhang; Yongguo Li; Wenhui Jiang; Qian Li; Yinghua Lan
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

10.  Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma.

Authors:  Norio Akuta; Yusuke Kawamura; Fumitaka Suzuki; Satoshi Saitoh; Yasuji Arase; Shunichiro Fujiyama; Hitomi Sezaki; Tetsuya Hosaka; Masahiro Kobayashi; Yoshiyuki Suzuki; Mariko Kobayashi; Kenji Ikeda; Hiromitsu Kumada
Journal:  BMC Gastroenterol       Date:  2016-12-12       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.